Regulatory Requirements for Nanotechnology-Based RNA Vaccines Therapeutic
Regulatory Requirements for Nanotechnology-Based RNA Vaccines and Therapeutics, a quick-start guide The Intracellular Drug Delivery Centre (IDDC) is a Centre of Excellence led by CPI in partnership with Medicines Discovery Catapult and three leading universities: the University of Strathclyde, the University of Liverpool and Imperial College London. Funded by Innovate UK’s Transforming Medicines Manufacturing programme, […]
Preparation, Characterisation and in vitro Assessment of siRNA-loaded Lipid-Based Nanoparticles
This paper demonstrates the combined in vitro capabilities of Seda Pharmaceutical Development Services in the manufacture and physical characterisation of lipid-based nanoparticles for nucleic acid delivery, coupled with the advanced in vitro characterisation capabilities of Medicines Discovery Catapult (MDC). Together, these organisations can support the design, prototype manufacture and screening of complex medicines ready for […]
MDC Connects: A Guide to Complex Medicines
MDC Connects was a series of weekly webinars which ran in 2021, a guide to Complex Medicines and RNA Therpapeutics. The sessions set out to educate, inform, and advise the community in drug discovery and drug delivery, focusing on recent trends and practice, encapsulating insight from experts in these areas. The sessions were aimed at small […]
Narration of the State of the Discovery Nation 2021 Report
A new wave of medicines has emerged in recent years, to supplement the established small and large molecule platforms. These complex medicines will become as important as traditional small molecule drugs in the coming years, with market values of hundreds of billions of pounds. Hear from our CSO, Prof. Peter Simpson as he talks about […]
State of the Discovery Nation 2021
Complex medicines will become as important as traditional small molecule drugs in the coming years, with market values of hundreds of billions of pounds. Pharmaceutical and biotech companies working in complex medicines in the UK include those specialising in antibody-drug conjugates, firms developing oligonucleotide therapeutics, entities focusing on proprietary delivery technologies for a range of […]
Webinar – Complex Medicines: Ready for the Clinic/Scaling up for Success
The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs. MDC Connects 2021: A Guide to Complex Medicines is a […]
Webinar – Complex Medicines: Understanding Safety & Efficacy
The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs. MDC Connects 2021: A Guide to Complex Medicines is a […]
Webinar – Complex Medicines: A Glance at Novel Drug Delivery Systems
The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs. MDC Connects 2021: A Guide to Complex Medicines is a […]
Webinar – Complex Medicines: Understanding the Interplay with Biological Systems
The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs. MDC Connects 2021: A Guide to Complex Medicines is a […]